---
figid: PMC7757414__fonc-10-599933-g001
figtitle: Targeted therapies available and in development in Acute Myeloid Leukemia
  (AML)
organisms:
- Homo sapiens
- Mus musculus
- Candida dubliniensis
organisms_ner:
- Homo sapiens
- Mus musculus
- Danio rerio
pmcid: PMC7757414
filename: fonc-10-599933-g001.jpg
figlink: pmc/articles/PMC7757414/figure/f1/
number: F1
caption: 'Targeted therapies available and in development in Acute Myeloid Leukemia
  (AML). Many tyrosine kinases inhibitors are either currently available or in development.
  These include: Fms-Like Tyrosine Kinase 3 (FLT3) inhibitors (such as sorafenib,
  quizartinib, gilteritinib, crenolanib), pan-kinase inhibitors (including midostaurin),
  FLT3 and KIT inhibitors (including pacritinib), Janus Kinase-2 (JAK2) and interleukine-1
  Receptor (IL-1R) Associated Kinases 1/4 (IRAK1/4) inhibitors, the IRAK4 inhibitor
  Ca-4948, the JAK2 inhibitor ruxolitinib, NRAS, KRAS and MAP Kinases (MAPK) inhibitors
  (such as vemurafenib, pazopanib, tivozanib), mTOR inhibitors (everolimus and dactolisib),
  TEC kinases inhibitors (including ibrutinib), and vascular and endothelial growth
  factor receptor (VEGFR) inhibitor cediranib. Several targeted-drugs are available,
  or in development, for transcription factors: ivosidenib, an Isocitrate Deshydrogenase-1
  (IDH1) inhibitor, enasidenib, an IDH2 inhibitor, azacytidine, decitabine, guadecitabine
  as hypomethylated agents, the histone deacetylase vorinostat and panobinostat, DS-3201b,
  a zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitor, pinometostat,
  a DOT1-like histone lysine methyltransferase (DOT1L) inhibitor, crizotinib, the
  Bcl6 Corepressor (BCOR) inhibitor, OTX015, a cyclin-dependent kinase 9/bromodomain
  and extraterminal (CDK9/BET) inhibitor, and elesclomol, a TP53 inhibitor. Selinexor
  inhibits the XPO1 exporter, which inhibits leukemic activity of mutated NPM1 proteins.
  Glasdegib inhibits smoothened multi-transmembrane (SMO), a member of the Hedgehog
  pathway. Tagraxofusp inhibits CD123, whereas IMGN632 transports chemotherapy through
  CD123 internalization, as does gemtuzumab ozogamicin and SGN-CD33A through CD33.
  Venetoclax inhibits the BCL2 anti-apoptotic protein. Several microenvironment targeted
  drug are in development: etomoxir inhibits fatty acid oxidation metabolism, tigecycline
  inhibits mitochondrial heterocellular transfer, thus inhibiting drug resistance
  exchange, ulocuplumab inhibits CXCR4/CXCL12 interaction from inducing leukemia myeloid
  cell migration, mirabegron, an agonist for sympathetic neuropathy β3-adrenergic
  receptor (β3-AR), and cavtratin, the NO synthase inhibitor.'
papertitle: 'Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development
  and Pre-Clinical Therapeutics.'
reftext: Xavier Roussel, et al. Front Oncol. 2020;10:599933.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8753137
figid_alias: PMC7757414__F1
figtype: Figure
redirect_from: /figures/PMC7757414__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7757414__fonc-10-599933-g001.html
  '@type': Dataset
  description: 'Targeted therapies available and in development in Acute Myeloid Leukemia
    (AML). Many tyrosine kinases inhibitors are either currently available or in development.
    These include: Fms-Like Tyrosine Kinase 3 (FLT3) inhibitors (such as sorafenib,
    quizartinib, gilteritinib, crenolanib), pan-kinase inhibitors (including midostaurin),
    FLT3 and KIT inhibitors (including pacritinib), Janus Kinase-2 (JAK2) and interleukine-1
    Receptor (IL-1R) Associated Kinases 1/4 (IRAK1/4) inhibitors, the IRAK4 inhibitor
    Ca-4948, the JAK2 inhibitor ruxolitinib, NRAS, KRAS and MAP Kinases (MAPK) inhibitors
    (such as vemurafenib, pazopanib, tivozanib), mTOR inhibitors (everolimus and dactolisib),
    TEC kinases inhibitors (including ibrutinib), and vascular and endothelial growth
    factor receptor (VEGFR) inhibitor cediranib. Several targeted-drugs are available,
    or in development, for transcription factors: ivosidenib, an Isocitrate Deshydrogenase-1
    (IDH1) inhibitor, enasidenib, an IDH2 inhibitor, azacytidine, decitabine, guadecitabine
    as hypomethylated agents, the histone deacetylase vorinostat and panobinostat,
    DS-3201b, a zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitor, pinometostat,
    a DOT1-like histone lysine methyltransferase (DOT1L) inhibitor, crizotinib, the
    Bcl6 Corepressor (BCOR) inhibitor, OTX015, a cyclin-dependent kinase 9/bromodomain
    and extraterminal (CDK9/BET) inhibitor, and elesclomol, a TP53 inhibitor. Selinexor
    inhibits the XPO1 exporter, which inhibits leukemic activity of mutated NPM1 proteins.
    Glasdegib inhibits smoothened multi-transmembrane (SMO), a member of the Hedgehog
    pathway. Tagraxofusp inhibits CD123, whereas IMGN632 transports chemotherapy through
    CD123 internalization, as does gemtuzumab ozogamicin and SGN-CD33A through CD33.
    Venetoclax inhibits the BCL2 anti-apoptotic protein. Several microenvironment
    targeted drug are in development: etomoxir inhibits fatty acid oxidation metabolism,
    tigecycline inhibits mitochondrial heterocellular transfer, thus inhibiting drug
    resistance exchange, ulocuplumab inhibits CXCR4/CXCL12 interaction from inducing
    leukemia myeloid cell migration, mirabegron, an agonist for sympathetic neuropathy
    β3-adrenergic receptor (β3-AR), and cavtratin, the NO synthase inhibitor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - NOS3
  - NANOS3
  - SIK1
  - SIK2
  - SIK3
  - SMO
  - SMOX
  - IRAK1
  - IRAK4
  - TEC
  - KRAS
  - HRAS
  - NRAS
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - MTOR
  - CD33
  - DNER
  - CDK9
  - CD48
  - BCL2
  - H1-0
  - H1-1
  - H1-2
  - H1-3
  - H1-4
  - H1-5
  - H1-6
  - H1-7
  - H1-8
  - H1-10
  - .na.character
  - H2AB1
  - H2AJ
  - H2AZ2
  - H2AX
  - MACROH2A1
  - MACROH2A2
  - H2AZ1
  - H2AC1
  - H2AC6
  - H2AC7
  - H2AC12
  - H2AC14
  - H2AC21
  - H2AC20
  - H2AC25
  - H2BC1
  - H2BC3
  - H2BC5
  - H2BC9
  - H2BC11
  - H2BC12
  - H2BC13
  - H2BC14
  - H2BC15
  - H2BC17
  - H2BC18
  - H2BC19P
  - H2BC20P
  - H2BC21
  - H2BC26
  - H2BC12L
  - H2BW2
  - H2BW1
  - H3-4
  - H3-5
  - H4C7
  - IDH1
  - EZH2
  - BCOR
  - TP53
  - DNMT3A
  - XPO1
  - IL3RA
  - IL1RAP
  - IL1R1
  - IL1RL1
  - ADRB3
  - FLT3
  - KIT
  - JAK2
  - KDR
  - FLT1
  - FLT4
  - CXCR4
  - Nos3
  - Sik1
  - Ptk6
  - Nop58
  - Smo
  - Smox
  - Irak1
  - Irak4
  - Tec
  - Nr4a3
  - ras
  - Hras
  - Kras
  - Rem1
  - Mtor
  - Cd33
  - Ptprj
  - Dner
  - Cdk9
  - Cd48
  - Bcl2
  - Idh1
  - Ezh2
  - Bcor
  - Trp53
  - Dnmt3a
  - Xpo1
  - Il3ra
  - Il1rap
  - Flt3
  - Kit
  - Jak2
  - Cxcr4
  - smo
  - irak1
  - irak4
  - pak2a
  - itpka
  - tec
  - itk
  - rab1ab
  - mtor
  - cdk9
  - bcl2a
  - idh1
  - ezh2
  - bcor
  - tp53
  - xpo1b
  - il1rap
  - il1rl1
  - flt3
  - kita
  - jak2b
  - cxcr4b
  - Midostaurin
  - Sorafenib
  - Quizartinib
  - Gilternitinib
  - Cytarabine
  - Anthracycline
  - Crenolanib
  - Pacritinib
  - Cediranib
  - Entospletinib
  - Tyrosine
  - Ibrutinib
  - Everolimus
  - Vemurafenib
  - Pazopanib
  - Tivozanib
  - Tigecycline
  - ozogamicin
  - OTX015
  - Co123
  - Ivosidenib
  - Crizotinib
  - Azacytidine
  - Decitabine
  - Guadecitabine
  - 1RAP O
  - AML
---
